

A discrete choice experiment of preferences for genetic counselling among Jewish women seeking cancer genetics services

S Peacock^{1,2}, C Apicella³, L Andrews⁴, K Tucker⁴, A Bankier⁵, MB Daly⁶ and JL Hopper^{*,3}

¹British Columbia Cancer Agency, Cancer Control Research, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada; ²Department of Health Care and Epidemiology, University of British Columbia, 5804 Fairview Avenue, Vancouver, British Columbia V6T 1Z3, Canada; ³Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, School of Population Health, The University of Melbourne, Level 2, 723 Swanston Street, Carlton, Victoria 3053, Australia; ⁴Hereditary Cancer Clinic, Prince of Wales Hospital, High St, Randwick, New South Wales 2031, Australia; ⁵Genetic Health Services Victoria, Royal Children's Hospital, Flemington Road, Parkville, Victoria 3052, Australia; ⁶Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111-2497, USA

To determine which aspects of breast cancer genetic counselling are important to Ashkenazi Jewish women, a discrete choice experiment was conducted. Participants consisted of 339 Australian Ashkenazi Jewish women who provided a blood sample for research used to test for Ashkenazi Jewish ancestral mutations in the genes BRCA1 and BRCA2, and were offered their genetic test result through a cancer genetics service. Main outcome measures were women's preferences for, and trade-offs between, the genetic counselling aspects of providing cancer, gene, and risk information (information); giving advice about cancer surveillance (surveillance); preparing for genetic testing (preparation); and, assistance with decision-making (direction). Respondents most valued information, about twice as much as advice about surveillance, four times as much as preparation for testing, and nine times as much as assistance with decision-making, which was least valued. Women's preferences were consistent with the major goals of genetic counselling, which include providing information and surveillance advice, and avoiding direction by facilitating autonomous decision-making. There were differences between the women in which aspects they most favoured, suggesting that counselling that elicits and responds to clients' preferences is more likely to meet clients' needs.

British Journal of Cancer (2006) 95, 1448–1453. doi:10.1038/sj.bjc.6603451 www.bjcancer.com

© 2006 Cancer Research UK

Keywords: Ashkenazi; breast cancer; BRCA1 and BRCA2; discrete choice experiment; client preferences; genetic counselling

Shortly after the cloning of the breast cancer susceptibility genes BRCA1 and BRCA2, three specific mutations in BRCA1 and BRCA2 were found to be 20 times more common in individuals of Ashkenazi Jewish descent than in the general population (Struwing *et al*, 1997). These ancestral mutations are thought to account for 20% of all breast cancer in Ashkenazi Jewish women (Satagopan *et al*, 2001). Carriers of a mutation in either of these genes are at 40–60% lifetime risk of developing breast cancer and 20–40% lifetime risk of developing ovarian cancer (Robson *et al*, 1997; Fodor *et al*, 1998; Hartge *et al*, 1999; Satagopan *et al*, 2001).

In the past decade, there has been a rapid increase in the demand for, and availability of, breast cancer genetics services (Thompson *et al*, 1995). These services aim to provide women with an estimate of their risk of developing breast and ovarian cancer based on their family history, and in some cases, genetic testing for mutations in BRCA1 and BRCA2 is offered. These services may further aim to improve psycho-social outcomes for clients by inclusion of other specialities and techniques, including, facilitating autonomous decision-making about genetic testing and risk-

reduction options, preparing clients for the possible outcomes of genetic testing, and offering family or group therapy sessions. In recent years, many services have established multidisciplinary teams including surgeons, oncologists, and gynaecologists so that breast and ovarian cancer surveillance advice can be provided.

Outcomes of genetic counselling may relate to *process issues*, or may relate to desired *client outcomes*. Process issues, such as satisfaction with consultation waiting time, location, duration of counselling sessions, and type of service provider, have been examined in a number of studies (Shiloh *et al*, 1990; Bernhardt *et al*, 2000; Brain *et al*, 2000; Metcalfe *et al*, 2000; Wilson *et al*, 2000; Holloway *et al*, 2004; Pieterse *et al*, 2005a,b). Client outcomes are more difficult to measure than process issues, but are more salient for evaluating and informing service delivery (Clarke *et al*, 1996; Cappelli *et al*, 2001). Desired client outcomes, such as reduced anxiety, improved genetic knowledge, and risk perception, have received some attention in the literature (Bernhardt *et al*, 2000; Metcalfe *et al*, 2000; Pieterse *et al*, 2005a,b).

Desired client outcomes may be influenced by several factors including clients' needs, their expectations and their preferences before counselling, and also the fulfilment, or perceived fulfilment, of these factors after counselling. Studies of expectations before genetic counselling have shown that clients often do not know the procedure or structure of the counselling appointment, sometimes resulting in the client feeling that he or she was inadequately

*Correspondence: Professor JL Hopper;

E-mail: j.hopper@unimelb.edu.au

Received 5 April 2006; revised 25 September 2006; accepted 28 September 2006

prepared (Hallowell *et al*, 1997; Stadler *et al*, 1998; Berkenstadt *et al*, 1999; Bernhardt *et al*, 2000; Holloway *et al* 2004). Studies of preferences measured before genetic counselling have further shown that clients have high preference for information, although it is difficult to interpret findings regarding preferences for aspects other than information given clients' lack of knowledge about the counselling process before attendance (Cohn *et al*, 2003; Tiller *et al*, 2005).

In this study, we elicited preferences for genetic service delivery in Jewish women who had previously participated in a BRCA1 and BRCA2 genetic testing programme, and so had knowledge of the procedures of genetic counselling. The aim of this study was to measure strength of preference for the different aspects of genetic counselling outcomes in these women. Discrete choice experiments are a theoretically valid technique developed by psychologists and economists for eliciting preferences, and are particularly well suited to eliciting preferences for the wide range of health and nonhealth benefits potentially derived from using health services (Ryan, 1999, 2004; Ryan and Farrar, 2000; Sculpher *et al*, 2004). We used a discrete choice experiment to provide robust information about what aspects clients *want most* from genetic counselling, the *relative value* they place on different counselling aspects, and *how much value* they place on the different aspects.

MATERIALS AND METHODS

Study sample

Eligible women were participants in the Australian Jewish Breast Cancer Study (AJBCS) (Apicella *et al*, 2003) who had previously received their genetic test results and enrolled in the study at least

6 months earlier. Participants recruited in the previous 6 months were excluded because many had not yet attended a genetic clinic for genetic counselling and result disclosure appointments. At recruitment, participants were administered a structured questionnaire developed by the Breast Cancer Family Registry, provided a blood sample that was tested for the Jewish ancestral mutations in BRCA1 and BRCA2, and received genetic information (John *et al*, 2004). Most women subsequently received their genetic test result through one of six state-funded cancer genetics services, as described previously (Apicella *et al*, 2006).

Discrete choice experiment

A follow-up questionnaire was mailed to all 339 participants. The questionnaire included a discrete choice experiment for preferences of attributes (aspects) of genetic counselling. These attributes were identified through reviews of the peer reviewed and policy/practice literature on genetic counselling, consultation with clinical geneticists, genetic counsellors, heads of genetic services, psychologists, and interviews with participants (Apicella *et al*, 2006). The four identified attributes included in the discrete choice experiment were: providing and explaining cancer, gene and risk information (Information); explaining options and giving advice about appropriate surveillance for breast and ovarian cancer (Surveillance); preparing for the outcomes of genetic testing (Preparation); and, receiving help in deciding whether or not to have a genetic test (Direction).

Descriptions were developed for each of the counselling attributes to help participants understand the nature of each that they were being asked to consider (see Figure 1). The critical task in describing attributes was to ensure they captured the desired client outcomes relevant to women attending the participating

SECTION H *This section asks what you PREFER from genetic clinics. Your answers may help to improve the genetic counselling and testing appointments, to provide a better service. To answer these questions, we ask you first to consider some potential topics for discussion at a genetic clinic (below), which you will be asked about in following questions.*

Potential topics for discussion at the genetic counselling appointment include:

<p>1. Genetic and cancer risk information (information)</p> <p>Counsellors and doctors provide information about breast and ovarian cancer and associated genes; they provide an estimate of your risk of developing breast or ovarian cancer given your personal and family cancer history.</p> <p>2. Preparation for testing (preparation)</p> <p>Counsellors and doctors discuss the possible benefits and limitations of having a genetic test, to help you to get ready for possible good or bad news, how you might feel after learning your test result, and any other personal issues relating to the test which may be of concern to you.</p> <p>3. Surveillance advice (surveillance)</p> <p>Counsellors and doctors talk to you about options for early detection of breast and ovarian cancer and provide recommendations for the frequency of mammography, ultrasound and other means of early detection appropriate for you.</p> <p>4. Deciding whether or not to have a genetic test (direction)</p> <p>Counsellors and doctors discuss the decision whether or not to have a genetic test. In particular, they would give their opinion as to whether you should go through genetic testing, to help give you direction in deciding what to do.</p>

1. Please rank these four topics in order of importance to you using a scale of 1 - 4, where 1 is the most important issue for discussion and 4 the least important. Please place a number in EVERY box.

	Rank
1. Information	
2. Preparation	
3. Surveillance	
4. Direction	

Figure 1 Attribute-ranking question used in the follow-up questionnaire.

3. Which appointment would you prefer?

1. Information
2. Preparation
3. Surveillance
4. Direction

Which would you prefer? (tick one only)

Appointment A	Appointment B
Amount of discussion	Amount of discussion
Some	A lot
A lot	None
A lot	
None	A lot

Prefer A Prefer B

Figure 2 Example of a discrete choice experiment question used in the follow-up questionnaire.

genetics services. To this end, clinical geneticists and counsellors who counselled the participants at these services played a central role in developing the descriptions. The four items and their descriptions were developed to capture information, emotional and psychosocial support, surveillance advice, and direction outcomes relevant to their practices.

Respondents were asked to rank their preferences for each of the four attributes at a genetic counselling appointment, where rank one is their most preferred and rank four is their least preferred. Strength of preference for each was then measured using a discrete choice experiment (see Figure 2).

Discrete choice experiments measure preferences by analysing individuals' responses to questions about choices they would make in hypothetical, yet realistic, situations. Respondents are asked to choose their preferred option (in this case different counselling appointments described by a unique combination of different levels for each of the counselling attributes) from a series of pairwise choices. A probabilistic discrete choice model was used to analyse the data.

Each discrete choice question asked respondents to choose between two hypothetical genetic counselling appointments described in terms of different levels of the four counselling attributes. Scenarios were paired randomly. Three attribute levels were used in the experimental design according to the amount of discussion – none, some, or a lot – devoted to each attribute during a counselling appointment. Respondents were therefore asked which of the two hypothetical genetic counselling appointments they would prefer, where alternative appointments were described in terms of different levels for the four attributes (see Figure 2). The SPEED computer package was used to select the optimal subset of scenarios, making the number of discrete choice questions manageable (Bradley, 1991).

An internal consistency test was included with the discrete choice experiment. This involved presenting a choice of counselling appointments with attribute levels such that all respondents should choose the same appointment. Only responses that showed internal consistency were included in the subset for analysis.

Statistical analysis

A random effects probit regression model was used to analyse the discrete choice data (Ryan and Farrar, 2000) using Stata v8.2.

RESULTS

Respondents

Of the 339 AJBCS participants who were sent the follow-up questionnaire (average 44 months after enrolment in the study), 256 (76%) were completed and returned. Table 1 shows the mean (s.d.) age of respondents was 52.6 years (12.0). The mean number of children was 2.0 (1.2). The mean genetic knowledge score was 6.8 (1.9). The mean State Trait Anxiety Inventory score was 38.8

Table 1 Descriptive characteristics of respondents

Personal characteristic	n	Per cent
Age N = 210 (years)		
25–54	127	(60)
55–74	74	(35)
75+	9	(4)
Mean (s.d.)	52.56 (11.96)	
Number of children N = 205		
0	33	(16)
1	21	(10)
2 or 3	138	(67)
4 or more	13	(6)
Mean (s.d.)	1.97 (1.19)	
University degree N = 210		
Yes	104	(50)
No	106	(50)
Breast cancer N = 208		
Yes	72	(35)
No	136	(65)
Family history (first- and second-degree relative) N = 207		
1 case breast cancer	74	(36)
2 cases breast cancer	51	(25)
3 or more cases breast cancer	52	(25)
Carrier of ancestral mutation	30	(14)
Genetic test result received N = 210		
Yes	187	(89)
No	23	(11)
Genetic knowledge (max. 9) N = 209		
1–3 (poor)	19	(9)
4–6 (fair)	44	(21)
7–9 (good)	146	(70)
Mean (Std. dev)	6.75 (1.94)	
Anxiety (STAI-Trait) N = 206		
<40	118	(57)
40–54	67	(33)
55–70	21	(10)
Mean (s.d.)	38.84 (10.43)	
Recent death of a relative N = 202		
Yes	44	(22)
No	158	(78)
Recent cancer of a relative N = 202		
Yes	42	(21)
No	160	(79)

(10.4). Thirty participants were found to be mutation carriers. Older women had more children ($P < 0.01$) and were more likely to have had cancer ($P < 0.01$). Younger women were more likely to

have a university degree ($P < 0.01$), and had better genetic knowledge ($P < 0.01$). Recent death in the family was associated with a strong family history of cancer (three or more cases of breast or ovarian cancer in first- and second-degree relatives) ($P < 0.01$) and recent cancer diagnosis in the family ($P < 0.01$).

Simple attribute ranking

Simple attribute-ranking preferences are presented elsewhere (Apicella *et al*, 2006). More than 60% of respondents ranked information as the most important attribute. Approximately 20 and 15% of respondents ranked surveillance and preparation as the most important attribute, respectively. Only 5% ranked direction as most important. More than 50% of respondents ranked direction as the least important attribute. Approximately 20% ranked surveillance, 25% preparation, and 5% information as least important, respectively. Preferences were not significantly different between the mutation carriers and noncarriers (Apicella *et al*, 2006). Rankings for the most important attribute for mutation carriers and noncarriers, respectively, were 67 and 61% for information; 13 and 20% for surveillance; 17 and 14% for preparation; 3 and 5% for direction.

Discrete choice experiment

Of the 209 women who completed all five discrete choice questions, 193 (92%) passed the consistency test. The random effects probit model was fitted using responses from these 193 respondents (Table 2). All main effects, the β_j coefficients, were positive and significant at the 1% level, except direction, which was significant at the 5% level, showing that increased amounts of discussion for each attribute were associated with increased utility (attributes are monotonically increasing in levels).

The most important attribute was information, followed by surveillance, and then preparation (Table 2). The least important attribute was direction. The main effects, statistically significant for all four attributes, showed that increasing the level (from none to some or from some to a lot) of discussion of information, utility increased by 0.997. Increasing the level of discussion of surveillance, preparation, and direction increased utility by 0.463, 0.267, and 0.114, respectively.

Table 3 shows the relative value, or importance, of the different attributes, given by the ratios ($\beta_{\text{info}}/\beta_{\text{dirn}}$) of the main effects. In

this study, women would give up 8.75 units of discussion of direction to get an extra unit of discussion of information. That is, information was found to be almost nine times as important as direction. Alternatively, it could be viewed that women would only give up 0.11 units of discussion of information to get an extra unit of discussion of direction. These data also show that discussion of information was more than three times as important as discussion of preparation, and more than twice as important as discussion of surveillance. Similarly, discussion of surveillance was four times more important than discussion of direction, and discussion of preparation was more than twice as important as discussion of direction.

The effects of respondents' personal characteristics and experiences on the relative value of attributes were examined to determine whether preferences vary systematically between respondents. This was performed by modelling potential interactions between characteristics and preferences in the regression model (segmentation analysis). Personal characteristics included demography, education, parity, psychological well-being, personal and family cancer history, mutation carrier status, and genetic knowledge. No statistically significant relationships were identified.

DISCUSSION

Women had highest preference for information, valuing it almost nine times more than direction in decision-making about genetic testing. This is consistent with the major aims of cancer genetic services, which include providing cancer, genetic and risk information, and facilitating autonomous decision-making. Women also had high preference for discussion of breast and ovarian cancer surveillance options, valuing it twice as much as preparation for possible outcomes of genetic testing, and four times as much as direction in decision-making about genetic testing. This provides evidence that the shift towards a multidisciplinary team, which includes oncologists and surgeons able to provide surveillance advice is consistent with women's preferences for genetic counselling. The discrete choice experiment results are entirely consistent with results from attribute-ranking questions presented in Apicella *et al* (2006).

Although many women preferred information most, and assistance with decision-making least, there were differences between women in which aspects they most favoured. In particular, we found that some women valued preparation highly, whereas others placed least value on this aspect of genetic counselling. Since analysing these data, we have become aware of another study which has similarly found that in general, clients preferred information most and emotional support least, although a subset had high preference for emotional support (Pieterse *et al*, 2005b).

The results from this study suggest that a uniform and structured genetic counselling appointment may not be the best method of service delivery, as preferences vary between clients, and fulfilment of clients' preferences are important for achieving desired client outcomes. This has also been demonstrated recently by Pieterse *et al* (2005b), who showed that desired client outcomes such as increased perceived personal control and reduced anxiety are significantly positively associated with clients' perceptions that their preferences for service delivery were met. That is, studies that help to identify client preferences both in general and in specific subgroups may assist in improving the delivery of genetic services.

Participants of this study have undergone genetic counselling, and most have received their genetic test result, meaning that they are well placed to identify attributes of genetic services that are important to users of those services (Genetic Interest Group, 1998; Royal College of Physicians, 1998). The importance of eliciting

Table 2 Random effects probit model results

	Main effect ^a (β_j)	s.e.	95% CI	$P > z $
Information	0.997	0.113	0.776–1.218	0.000
Surveillance	0.463	0.036	0.393–0.533	0.000
Preparation	0.267	0.045	0.182–0.353	0.000
Direction	0.114	0.047	0.023–0.206	0.014

CI = confidence interval. Individuals = 193; observations = 965. Log-likelihood = -510.209; Wald $\chi^2(4) = 250.15$; Prob. $> \chi^2 = 0.000$. ^aAn alternative approach to estimating the main effects model is to use dummy variables for categorical attribute levels in the independent variable set. However, this approach becomes problematic owing to collinearity in the set of dummy variables.

Table 3 Relative value of attributes: ratios of main effects

	Main effect (β_j)	$\beta_j/\beta_{\text{info}}$	$\beta_j/\beta_{\text{surv}}$	$\beta_j/\beta_{\text{prep}}$	$\beta_j/\beta_{\text{dirn}}$
Information	0.997	1.00	2.15	3.73	8.75
Surveillance	0.463	0.46	1.00	1.73	4.06
Preparation	0.267	0.27	0.58	1.00	2.34
Direction	0.114	0.11	0.25	0.43	1.00

preferences from respondents with first-hand experience of genetics and genetics services in understanding the attributes of genetics services has been recognised elsewhere (Wilson *et al*, 2000).

Given *a priori* expectations, the discrete choice experiment results are plausible, and provide further evidence that the technique can be successfully applied in health care. Discrete choice experiments have been shown to provide internally valid and consistent responses (Viney *et al*, 2002; Ryan and Gerard, 2003; Ryan *et al*, 2003). However, this may depend on study context (Ryan and Gerard, 2002), and there is some evidence that some respondents may not trade-off attributes, but adopt simpler decision heuristics (Scott, 2002; Lloyd, 2003). Although the choices presented to respondents are hypothetical, this allows researchers to have complete control over experimental design and ensures statistical robustness (Ubach *et al*, 2003). An important question with any stated preference technique is that of external validity: would respondents make the same choices in reality? Surveying respondents with first-hand experience genetics services, and evidence from other areas such as the valuation of environmental goods and services means that we can be optimistic (Wilson *et al*, 2000; Ryan, 2004). Clearly, future research on these topics is warranted.

It remains to be seen whether results from this study are generalisable to other populations and to other types of genetic testing, owing to differences in the characteristics of participants of this study and of other populations seeking cancer genetic counselling. Such differences include; specific testing with a more definitive outcome was conducted in the Ashkenazi Jewish population, whereas there is often no definitive outcome from BRCA1 and BRCA2 testing in the general population; the extent of family cancer history of participants may differ from other populations undergoing BRCA1 and BRCA2 testing; and, other cultural groups may value counselling outcomes differently. Nonetheless, a study of preferences for cancer genetic counselling in a Dutch population found that clients had similar preferences to

those identified in this study of Australian Jewish women (Pieterse *et al*, 2005b), suggesting that findings from this study may apply to other populations.

The discrete choice experiment technique could be further used to elicit client preferences for a range of other health and nonhealth objectives relating to genetics services. In particular, access to genetics services may be improved if genetics testing becomes available through general practitioners on a widespread basis. However, this might be associated with a more limited service for clients, as most general practitioners will not have the time or level of genetics training as found in dedicated genetic clinics. A discrete choice experiment could be used to measure the value that clients place on improving access to genetics services relative to the amount of information and other aspects of genetic counselling that they would receive from their local family doctor compared to a genetic clinic.

ACKNOWLEDGEMENTS

This study was funded by the National Cancer Institute (USA) as part of the Breast Cancer Family Registry, and supported in Australia by the Australian National Health and Medical Research Council. Stuart Peacock is a Michael Smith Foundation for Health Research Scholar. We wish to express our appreciation to the women and their relatives who participated in this study. The views expressed in this paper are those of the authors, not the funding agencies.

Ethics approval: The study was approved by the Human Research Ethics Committees of the Peter MacCallum Cancer Institute (Melbourne), The Prince of Wales Hospital (Sydney), and The University of Melbourne. Written informed consent was obtained from all participants in accordance with each ethics committee's requirements.

REFERENCES

- Apicella C, Andrews L, Hodgson SV, Fisher SA, Lewis CM, Solomon E, Tucker K, Friedlander M, Bankier A, Southey MC, Venter DJ, Hopper JL (2003) Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a defined personal and family history in an Ashkenazi Jewish woman (LAMBDA). *Breast Cancer Res* 5: R206–R216, doi:10.1186/bcr644
- Apicella C, Peacock S, Andrews L, Tucker K, Bankier A, Daly MB, Hopper JL (2006) Determinants of preferences for genetic counselling in Jewish Women. *Fam Cancer* 5: 159–167, doi:10.1007/s10689-005-3871-7
- Berkenstadt M, Shiloh S, Barkai G, Katznelson MB, Goldman B (1999) Perceived personal control (PPC): a new concept in measuring outcome of genetic counseling. *Am J Med Genet* 82: 53–59, doi:10.1002/(SICI)1096-8628(19990101)82:1
- Bernhardt BA, Biesecker BB, Mastromarino CL (2000) Goals, benefits, and outcomes of genetic counseling: client and genetic counselor assessment. *Am J Med Genet* 94: 189–197
- Bradley M (1991) *User's Manual for SPEED Version 2.1 Stated Preference Experiment Editor and Designer*. Hague: Hague Consulting Group
- Brain K, Gray J, Norman P, France E, Anglim C, Barton G, Parsons E, Clarke A, Sweetland H, Tischkowitz M, Myring J, Stansfield K, Webster D, Gower-Thomas K, Daoud R, Gateley C, Monypenny I, Singhal H, Branston L, Sampson J, Roberts E, Newcombe R, Cohen D, Rogers C, Mansel R, Harper P (2000) Randomized trial of a specialist genetic assessment service for familial breast cancer. *J Natl Cancer Inst* 92: 1345–1351
- Cappelli M, Surh L, Humphreys L, Verma S, Logan D, Hunter A, Allanson J (2001) Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing. *Qual Life Res* 10: 595–607, doi:10.1023/A:1013123915272
- Clarke A, Parsons E, Williams A (1996) Outcomes and process in genetic counselling. *Clin Genet* 50: 462–469
- Cohn WF, Ropka ME, Jones SM, Miesfeldt S (2003) Information needs about hereditary breast cancer among women with early-onset breast cancer. *Can Detect Prev* 27: 345–352, doi:10.1016/j.cdp.2003.07.001
- Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST, Eng CM (1998) Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. *Am J Hum Genet* 63: 45–51
- Genetic Interest Group (1998) *Guidelines for Genetics Services. A Working Party Report*. London: GIG
- Hallowell N, Murton F, Statham H, Green JM, Richards MP (1997) Women's need for information before attending genetic counselling for familial breast or ovarian cancer: a questionnaire, interview, and observational study. *BMJ* 314: 281–283
- Hartge P, Struwing JP, Wacholder S, Brody LC, Tucker MA (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. *Am J Hum Genet* 64: 963–970
- Holloway S, Porteous M, Cetnarskyj R, Anderson E, Rush R, Fry A, Gorman D, Steel M, Campbell H (2004) Patient satisfaction with two different models of cancer genetic services in south-east Scotland. *Br J Cancer* 90: 582–589, doi:10.1038/sbjc6601562
- John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, Buys SS, Daly MB, O'Malley FP, Santella RM, Southey MC, Venne VL, Venter DJ, West DW, Whittemore AS, Seminara D, Breast Cancer Family Registry (2004) Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. *Breast Cancer Res* 6: R375–R389, Epub 2004 May 19, doi:10.1196/bcr901
- Lloyd AJ (2003) Threats to the estimation of benefit: are preference elicitation methods accurate? *Health Econ* 12: 393–402, doi:10.1002/nec.772

- Metcalf KA, Liede A, Hoodfar E, Scott A, Foulkes WD, Narod SA (2000) An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. *J Med Genet* 37: 866–874
- Pieterse A, van Dulmen S, Ausems M, Schoemaker A, Beemer F, Bensing J (2005a) QUOTE-gene(ca): development of a counselee-centered instrument to measure needs and preferences in genetic counseling for hereditary cancer. *Psycho-oncology* 14: 361–375
- Pieterse AH, Ausems MG, Van Dulmen AM, Beemer FA, Bensing JM (2005b) Initial cancer genetic counseling consultation: change in counselees' cognitions and anxiety, and association with addressing their needs and preferences. *Am J Med Genet* 137A: 27–35
- Robson M, Dabney MK, Rosenthal G, Ludwig S, Seltzer MH, Gilewski T, Haas B, Osborne M, Norton L, Gilbert F, Offit K (1997) Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. *Genet Test* 1: 47–51
- Royal College of Physicians (1998) *Commissioning Clinical Genetics Services*. London: Royal College of Physicians
- Ryan M (1999) Using conjoint analysis to go beyond health outcomes: an application to *in vitro* fertilisation. *Soc Sci Med* 48: 535–546, doi:10.1016/S0277-9536(98)00374-8
- Ryan M (2004) Discrete choice experiments in health care. *BMJ* 328: 360–361, doi:10.1136/bmj.328.7436.360
- Ryan M, Farrar S (2000) Using conjoint analysis to elicit preferences for health care. *BMJ* 320: 1530–1533, doi:10.1136/bmj.320.7248.1530
- Ryan M, Gerard K (2002) Using discrete choice experiments in health economics: moving forward. In *Advances in Health Economics* Scott A, Maynard A, Elliott R (eds) pp 25–40. Chichester: Wiley
- Ryan M, Gerard K (2003) Using discrete choice experiments to value health care: current practice and future prospects. *Appl Health Econ Policy Analysis* 2: 55–64
- Ryan M, Watson V, Amaya-Amaya M (2003) Methodological issues in the monetary valuation of benefits in health care. *Exp Rev Pharmacoecon Outcomes Res* 3: 717–727
- Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB (2001) The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. *Cancer Epidemiol Biomark Prevent* 10: 467–473
- Scott A (2002) Identifying and analysing dominant preferences in discrete choice experiments: an application in health care. *J Econ Psych* 23: 383–398, doi:10.1016/S0167-4870(02)00082-X
- Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M (2004) Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment. *BMJ* 328: 382–385, doi:10.1136/bmj.37972.497234.44
- Shiloh S, Avdor O, Goodman RM (1990) Satisfaction with genetic counseling: dimensions and measurement. *Am J Med Genet* 37: 522–529
- Stadler MP, Mulvihill JJ (1998) Cancer risk assessment and genetic counseling in an academic medical center: consultands' satisfaction, knowledge, and behaviour in the first year. *J Genet Couns* 7: 279–297
- Struwing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. *N Engl J Med* 336: 1401–1408
- Thompson JA, Wiesner GL, Sellers TA, Vachon C, Ahrens M, Potter JD, Sumpmann M, Kersey J (1995) Genetic services for familial cancer patients: a survey of National Cancer Institute cancer centers. *J Natl Cancer Inst* 87: 1446–1455
- Tiller K, Meiser B, Gould L, Tucker K, Dudding T, Franklin J, Friedlander M, Andrews L (2005) Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer. *Psycho-Oncol* 14: 249–261, doi: 10.1002/pon.840
- Ubach C, Scott A, French F, Awramenko M, Needham G (2003) What do hospital consultants value about their jobs? A discrete choice experiment. *BMJ* 326: 1432–1442, doi:10.1136/bmj.326.7404.1432
- Viney R, Lancsar E, Louviere J (2002) Discrete choice experiments to measure preferences for health and health care. *Exp Rev Pharmacoecon Outcomes Res* 2: 319–326
- Wilson B, Ryan M, Haites N (2000) *Assessing User Preferences for, and Costs of, Genetic Counselling for Familial Cancer Risk in Scotland: A Cost-Utility Analysis Using Conjoint Analysis*. Scottish: Report to the Chief Scientist Office, Executive Health Department